Cholinesterase inhibitors, which are approved for the symptomatic treatment of mild to moderate AD, have been of interest for MCI treatment, but numerous studies have failed to indicate a benefit in reducing MCI or the progression to dementia [109,122]. The gene discussed is BCHE; the disease is dementia.